What is PRIME?

PRIME is a European consortium of research institutes, medical centres, companies, and societal stakeholders that is funded through an EU Horizon 2020 grant. From 2020 – 2024, PRIME will aim to unravel the insulin-dependent mechanisms that underly both somatic conditions (i.e. type 2 diabetes, obesity, metabolic syndrome) and brain disorders (i.e. Alzheimer’s disease, obsessive-compulsive disorder, autism spectrum disorders). Until now, very little attention has been paid to the role of insulin signaling in brain disorders, and the overlap (or ‘multimorbidity’) with somatic conditions.

Therefore, through PRIME, we aim to develop tools for improved diagnosis, clinical care and prevention of insulin-related lifespan multimorbidity.

Learn More

News & Events

11 March 2021

Upcoming PRIME Webinars!

* Tuesday 30 March at 16:00h (CEST): Neurodevelopmental Disorders (ASD, ADHD and OCD) – by prof. Jan Buitelaar

Autism Spectrum Disorder (ASD) and Attention-Deficit Hyperactivity Disorder (ADHD) are neurodevelopmental disorders with onset in early childhood by definition (ASD) or in most cases (ADHD). ASD is characterized by persistent problems in social interaction and communication and rigid patterns of behaviour, and ADHD by a pattern of inattentive and/or hyperactive-impulsive behaviours. ASD and ADHD have a strong phenotypic overlap and share genetic risk factors and neural underpinnings. They are thought to be due to early disruptions of brain development, at the prenatal or early post-natal stage. Obsessive-compulsive Disorder (OCD) is classified among the anxiety disorders, and characterized by a pattern of  recurring thoughts (called "obsessions") and/or behaviors that need to be repeated (called "compulsions") to an extent which generates distress or impairs general functioning. OCD mostly has onset around age 10 or later. This webinar will review the clinical characteristics, onset and course of these disorders, identify similarities and differences.

*Monday 17 May at 10:00h (CEST): Retinal and cognitive dysfunction in type 2 diabetes: unravelling the common pathways and identification of patients at risk of dementia – RECOGNISED - by prof. Noemi Lois

RECOGNISED aims at determining the usefulness of the retina as a tool to identify people with type 2 diabetes and cognitive impairment, and those at risk of developing cognitive decline and dementia.

More News